-
- Mechanism of Action: Retatrutide is often referred to as "Triple G" because it mimics three natural hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.
- Efficacy: In Phase 2 clinical trials, retatrutide demonstrated significant weight loss, with participants losing an average of up to 24.2% of their body weight over 48 weeks at the highest dose. These results have been described as more potent than current single or dual-agonist medications like semaglutide (Wegovy) and tirzepatide (Zepbound).
- Administration: It is administered as a once-weekly subcutaneous injection.
- Regulatory Status: Retatrutide is not an FDA-approved drug and is not safe or effective for any condition outside of supervised clinical trials. The FDA has explicitly stated that it cannot be used in compounding under federal law. Products sold online are research chemicals and not the legitimate investigational medicine.
- Potential Side Effects: The most common side effects are primarily gastrointestinal, similar to other GLP-1 agonists.